Stock listing
LS Exchange:A3EUTV NexImmune, Inc. Aktie
German listing (LS Exchange) of NexImmune, Inc. · home listing OTC:NEXI
Follow NexImmune, Inc. into a list and get an email when it puts out news.
Home listing price · OTC:NEXI
$0.0001 USD 0.0000 (0.0%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OTC:NEXI
- Day range
- $0.0001 – $0.0001 USDOct 30, 2026
- Market cap
- $139 USDAt the close on Oct 30, 2026 · price × 1.39M shares outstanding
- 52-week range
- $0.0001 – $0.0003 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $0 USDMedian day 0 shares · 60 days with no trades · last 3 months, Jul 30, 2026 – Oct 30, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:NEXI · Home | $0.0001 USD | 0.0000 (0.0%) | — | $0.0001 | $0.0001 | $0.0001 | $0.0001 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · OTC:NEXI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,365 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 100 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 550 | |
| $0.0001 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0001 | 100 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 171 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 178 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 132 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 |
Splits
1 split · OTC:NEXI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- LS Exchange:A3EUTV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LS Exchange
- Currency
- EUR
NexImmune, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Where NexImmune, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| OTC:NEXI · Home listing | OTC | United States | USD |
| Lang & Schwarz:A3EUTV | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3EUTV · This page | LS Exchange | Germany | EUR |
Valuation
price Oct 30, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NexImmune, Inc. · OTC:NEXI | US$139 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.31 |
| Chimeric Therapeutics Limited · ASX:CHM | US$293,554 | −US$220,748 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| ZyVersa Therapeutics, Inc. · OTC:ZVSA | US$810 | US$1.20B | n/a | n/a | n/a | n/a | n/a | n/a | -0.56 |
| Median of the others | US$164,053 | US$159,190 | 18.5× | 0.1× | −382.1% | 1.3× | 1.14 |
Events
| Quarter | Results |
|---|---|
| Q2 2024 | Aug 7, 2024 · After close |
| Q1 2024 | Apr 16, 2024 · After close |
| Q4 2023 | Feb 7, 2024 · Before open |
| Q3 2023 | Nov 17, 2023 · After close |
| Q2 2023 | Aug 10, 2023 · After close |
| Q1 2023 | May 15, 2023 · After close |
| Q4 2022 | Mar 28, 2023 · After close |
| Q3 2022 | Nov 14, 2022 · After close |
| Q2 2022 | Aug 15, 2022 · After close |
| Q1 2022 | May 12, 2022 · After close |
All 15 quarters
| Quarter | Results |
|---|---|
| Q4 2021 | Mar 9, 2022 · After close |
| Q3 2021 | Nov 12, 2021 · Before open |
| Q2 2021 | Aug 9, 2021 · After close |
| Q1 2021 | May 17, 2021 · After close |
| Q4 2020 | Feb 11, 2021 · After close |
Financials
Annual, in USD
Income statement
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.02M | 1.50M | 870.3K | 619.0K | 436.4K | 204.6K |
| Gross profit | -1.02M | -1.50M | -870.3K | -619.0K | -436.4K | -204.6K |
| Research and development | 18.3M | 47.1M | 37.5M | 17.8M | 15.2M | 8.00M |
| Selling, general and administrative | 13.0B | 15.9M | 15.8M | 10.0M | 5.71M | 5.24M |
| Operating income | -29.2M | -63.1M | -53.3M | -27.9M | -20.9M | -13.2M |
| Depreciation and amortization | 1.02M | 994.8K | 870.3K | 619.0K | 436.4K | 204.6K |
| EBITDA | -28.2M | -62.1M | -52.4M | -27.2M | -20.4M | -13.0M |
| Interest expense | 576.7M | 905.3K | 1.68M | 7.26K | 0 | |
| Income before tax | -32.3M | -62.5M | -50.9M | -29.9M | -20.5M | -12.8M |
| Income tax | -2 | -576.7M | 843.9K | 1.77M | -246.8K | 409.2K |
| Net income | -32.3M | 514.2M | -51.7M | -31.6M | -20.3M | -12.8M |
| Earnings per share, basic | -30.82 | 534.29 | -56.67 | -34.76 | -22.53 | -14.25 |
Balance sheet
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 3.20M | 34.6M | 30.3M | 5.03M | 9.13M | 426.0K |
| Short-term investments | 1.44M | 0 | 51.5M | 1.01B | 1.01M | 11.6M |
| Receivables | 74.5K | 6.42K | 73.6K | |||
| Inventory | -19.5K | 61.1K | ||||
| Current assets | 5.40M | 37.4M | 86.3M | 8.39M | 11.0M | 12.3M |
| Property, plant and equipment | 5.43M | 4.43M | 2.89M | 2.58M | 1.70M | |
| Total assets | 8.59M | 43.1M | 91.0M | 11.3M | 13.7M | 14.1M |
| Accounts payable | 1.34M | 2.38M | 1.05M | 2.76M | 1.17M | 860.7K |
| Current liabilities | 5.08M | 10.3M | 7.22M | 27.0M | 3.03M | 3.00M |
| Total debt | 68.8K | 1.02M | 19.1M | 53.6M | 35.0M | |
| Total liabilities | 5.08M | 10.8M | 7.27M | 27.1M | 3.11M | 3.33M |
| Shareholders' equity | 3.51M | 32.3M | 83.8M | -15.8M | 10.6M | 10.8M |
| Shares outstanding | 1.05M | 962.4K | 913.2K | 910.3K | 900.9K | 900.9K |
Cash flow
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Cash from operations | -31.4M | -51.2M | -45.8M | -26.4M | -19.4M | -11.1M |
| Capital spending | -48.7K | -1.26M | -2.35M | -864.7K | -1.25M | -937.8K |
| Free cash flow | -31.5M | -52.4M | -48.1M | -27.3M | -20.7M | -12.1M |
| Cash from investing | -44.5K | 50.3M | -53.8M | 221.9K | 9.42M | -12.6M |
| Cash from financing | 0 | 5.18M | 124.9M | 22.1M | 18.8M | 9.18M |
| Dividends paid | -377.6K | |||||
| Change in cash | -31.5M | 4.30M | 25.3M | -4.10M | 8.77M | -14.6M |
Cap table
Built by 6ix from NexImmune, Inc.’s releases
- Common shares
- 1,394,671
- Fully diluted
- 1,394,671
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,394,671 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,394,671 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sol J. Barer Other companies: Teva Pharmaceutical Industries Limited (Chairman of the Board Independent Director · Since at least Jan 1, 2018); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); CervoMed Inc. (Director · Nov 1, 2013 – Jul 24, 2014 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past) | Director · Feb 11, 2021 – Jul 5, 2023 · Past |
| Jerome Zeldis Other companies: NexGel, Inc (Director · Since at least Mar 8, 2021); PTC Therapeutics, Inc. (Director · Since at least Jun 19, 2013); Soligenix, Inc. (Board Director · Since at least Jun 22, 2011); MetaStat Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past); Beyond Air, Inc. (Director · Mar 14, 2017 – Mar 14, 2017 · Past); Sorrento Therapeutics, Inc. (See Remarks · Aug 12, 2016 – Nov 26, 2018 · Past); Streamex Corp. (Director · Jul 20, 2015 – Jul 14, 2020 · Past) | Executive VP of Research & Dev · Feb 11, 2021 – Apr 5, 2022 · Past |
| Zhengbin Yao Other companies: Alumis Inc. (Director · Since at least Jun 27, 2024); ArriVent BioPharma, Inc. (Chairman, Chief Executive Officer · Since at least Jan 25, 2024); Viela Bio Inc (Chief Executive Officer, Director · Oct 2, 2019 – Mar 13, 2021 · Past); Tanox Inc (Vice President of Research · Feb 15, 2006 – Nov 20, 2006 · Past) | Director · Feb 11, 2021 – Jul 5, 2023 · Past |
| Albert N Marchio II Other companies: Fresh Tracks Therapeutics Inc. (CEO and CFO, Director · Jan 24, 2023 – Dec 28, 2023 · Past); Brickell Biotech Inc (Chief Financial Officer · Dec 1, 2020 – May 5, 2022 · Past); PDS Biotechnology Corporation (Chief Accounting & Adm Officer · Sep 30, 2015 – Dec 31, 2018 · Past) | See Remarks · Apr 5, 2024 – Apr 5, 2024 · Past |
| Timothy Bertram Other companies: ProKidney Corp. (Chief Executive Officer, Director · Jul 11, 2022 – Jan 16, 2023 · Past); Tengion Inc (Pres Rsrch & Dev, & Chf Sc Ofc · Apr 9, 2010 – Mar 4, 2013 · Past) | Director · Feb 11, 2021 – Jul 5, 2023 · Past |
| Alan S Roemer Other companies: IN8bio, Inc. (Director · Since at least Jul 29, 2021) | Director · Feb 11, 2021 – Nov 21, 2023 · Past |
| Grant Verstandig | Director · Feb 11, 2021 – Jul 5, 2023 · Past |
| John Trainer | Chief Financial Officer · Feb 11, 2021 – Apr 4, 2023 · Past |
| Kristi Jones | President and CEO, Director · Feb 11, 2021 – Jun 11, 2024 · Past |
| Leena Gandhi | Director · May 5, 2022 – Jul 5, 2023 · Past |
All 15 people
| Person | Seat |
|---|---|
| Mathias Oelke | Chief Science Officer · Apr 5, 2022 – Apr 4, 2023 · Past |
| Paul D'Angio | Director · Feb 11, 2021 – Jul 5, 2023 · Past |
| Robert Douglas Knight | Chief Medical Officer · Feb 11, 2021 – Apr 5, 2022 · Past |
| Scott Carmer | President and CEO, Director · Feb 11, 2021 – Feb 17, 2021 · Past |
| Timothy Stover | VP, Corporate Controller · Aug 30, 2023 – Aug 30, 2023 · Past |
Log in to ask 6ix AI your own questions about NexImmune, Inc.